1-4 of 4
PierMannuccio Mannucci
Close
Sort by
Journal Articles

Genetic Risk Stratification to Minimize Inhibitor Risk with the Use of Recombinant Factor VIII Concentrates: A Sippet Analysis

Frits Rosendaal, MD PhD, Roberta Palla, PhD, Isabella Garagiola, PhD, Piermannuccio Mannucci, MD, Flora Peyvandi, MD PhD
Journal: Blood
Blood (2016) 128 (22): 325.
https://doi.org/10.1182/blood.V128.22.325.325
Published: 2016
Journal Articles

Risk Differential in Inhibitor Development in the First Days of Treatment By Product Class: A Sippet Analysis

Flora Peyvandi, MD PhD, Antonino Cannavò, MD, Isabella Garagiola, PhD, Roberta Palla, PhD, Frits Rosendaal, MD PhD, Piermannuccio Mannucci, MD
Journal: Blood
Blood (2016) 128 (22): 330.
https://doi.org/10.1182/blood.V128.22.330.330
Published: 2016
Journal Articles

Patient Preferences for Treatment Products in Hemophilia: A Conjoint Analysis (Conan Study Group).

Alessandro Gringeri, MD, MSc, Piermannuccio Mannucci, MD, Mara Monzini, PharmD, Luciana Scalone, PharmD, Lorenzo Mantovani, MSc, DSc
Journal: Blood
Blood (2004) 104 (11): 2203.
https://doi.org/10.1182/blood.V104.11.2203.2203
Published: 2004
Journal Articles

Hyperprothrombinemia may result in acquired activated protein C resistance

Armando Tripodi, Veena Chantarangkul, PierMannuccio Mannucci
Journal: Blood
Blood (2000) 96 (9): 3295–3296.
https://doi.org/10.1182/blood.V96.9.3295
Published: 2000